Home Newsfeeds Guggenheim Downgrades Albireo Pharma to Neutral

Guggenheim Downgrades Albireo Pharma to Neutral

Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.

byBenzinga Newsdesk

January 11, 2023

1 minute read

Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.

Needham Maintains Buy on Cardlytics, Lowers Price Target to $19

By Benzinga Newsdesk

August 3, 5:46 AM

Needham analyst Kyle Peterson maintains Cardlytics (NASDAQ:CDLX) with a Buy and lowers the price target from $24 to $19.

CDLX

Regulatory Headwinds Harm CBD Sales For Charlotte’s Web: YoY Drop In Q3 Revenue, Gross Profit

By Jelena Martinovic

November 9, 10:37 AM

Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) reported its third-quarter results on Thursday for the three months ended Sept. 2023, revealing a nearly 16% year-over-year decrease in revenue to $14.3 million.

CWBHF

Bath & Body Works FY23 Outlook: EPS $2.50 – $3.00 Vs. $3.64 Estimate, Revenue Decline To Mid-Single Digits

By Benzinga Newsdesk

February 23, 7:14 AM

2023 Outlook The company's forecast takes into consideration ongoing macroeconomic uncertainty and assumes a continuation of fourth quarter 2022 sales trends for the first half of fiscal 2023. The company expects

BBWI

Jim Cramer Says Tesla Stock Could Climb To $175 Today On Back Of Elon Musk Comments: ‘Everything That Was Bad Is Now Good’

By Adam Eckert

April 24, 1:35 PM

Although Tesla came up short of estimates on the top and bottom lines, the stock is taking off on Wednesday. Jim Cramer believes the move in Tesla shares is simply about sentiment.

TSLA

Guggenheim Downgrades Albireo Pharma to Neutral

Related Posts

Needham Maintains Buy on Cardlytics, Lowers Price Target to $19

Regulatory Headwinds Harm CBD Sales For Charlotte’s Web: YoY Drop In Q3 Revenue, Gross Profit

Bath & Body Works FY23 Outlook: EPS $2.50 – $3.00 Vs. $3.64 Estimate, Revenue Decline To Mid-Single Digits

Jim Cramer Says Tesla Stock Could Climb To $175 Today On Back Of Elon Musk Comments: ‘Everything That Was Bad Is Now Good’